Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Immunocore Holdings Ltd(IMCR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IMCR
11/05/2026: IMCR (1-star) is currently NOT-A-BUY. Pass it for now.
Immunocore Holdings Ltd is a commercial-stage biotechnology company centered on its proprietary ImmTAC technology, designed to redirect T-cells to target cancer. The company's primary strength is the commercial success of KIMMTRAK, the first approved TCR bispecific therapy, which provides a foundational revenue stream. Its growth story hinges on expanding this therapy's reach and advancing a clinical pipeline aimed at various solid tumors. Key risks include reliance on a single marketed product, significant R&D cash burn, and intense oncology competition. This stock may suit growth-oriented investors with a high risk tolerance who are willing to monitor ongoing clinical trial data and commercial adoption rates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers exposure to a novel platform technology with a clear growth trajectory in oncology. |
| Momentum investor | Mixed fit | Momentum is highly dependent on clinical trial outcomes and commercial sales growth, requiring careful timing. |
| Value investor | Weak fit | The company is not currently valued on traditional P/E or cash flow metrics due to its R&D stage. |
| Dividend investor | Weak fit | The company pays no dividends and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | The stock carries high volatility inherent to the biotechnology sector and clinical-stage risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are highly sensitive to clinical data updates and market sentiment. |
| Valuation risk | Medium / high | Future growth expectations are baked into the price, leaving little room for error. |
| Competition risk (oncology) | Medium / high | Large incumbents can rapidly pivot to compete in oncology niches. |
| Business quality | Medium | The company has a validated platform but is still building a stable commercial franchise. |
| Dividend income | Low / none | Investors should not expect any income from this security. |
| Execution risk | Medium / high | Clinical pipeline success is never guaranteed, and commercial scaling is challenging. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -4.23% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.51B USD | Price to earnings Ratio - | 1Y Target Price 62.73 |
Price to earnings Ratio - | 1Y Target Price 62.73 | ||
Volume (30-day avg) 491.0K shares | Beta 0.81 | 52 Weeks Range 27.50 - 40.71 | Updated Date 11/05/2026 |
52 Weeks Range 27.50 - 40.71 | Updated Date 11/05/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.36 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Global sales of KIMMTRAK for uveal melanoma. | Revenue comes from selling a specialized drug to hospitals and cancer treatment centers. |
| Collaboration and Licensing | Upfront payments, milestones, and royalties from R&D partnerships. | The company occasionally generates cash by letting other big drug companies use its technology. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 22.57 | Enterprise Value 1.10B | Price to Sales(TTM) 3.49 |
Enterprise Value 1.10B | Price to Sales(TTM) 3.49 | ||
Enterprise Value to Revenue 2.56 | Enterprise Value to EBITDA 84.49 | Shares Outstanding 51.50M | Shares Floating 45.83M |
Shares Outstanding 51.50M | Shares Floating 45.83M | ||
Percent Insiders 0.07 | Percent Institutions 103.08 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.